5-氟尿嘧啶与咪喹莫特治疗光化性角化病的真实世界比较
在加州北部大型综合医疗系统开展回顾性队列研究,纳入2007年确诊光化性角化病并随后使用5-氟尿嘧啶或咪喹莫特的成年成员共5700例。结果显示5-氟尿嘧啶在2年内降低后续AK累积风险优于咪喹莫特,但5年长期差异无统计学意义。
要点
- 5-氟尿嘧啶短期(2年)预防后续AK优于咪喹莫特。
- 5年长期风险差异未达统计学显著。
- 结果来自真实世界回顾性队列,需考虑混杂局限。
核心结论
- 5-氟尿嘧啶在短期预防后续光化性角化病方面似乎显著优于咪喹莫特,但长期无显著差异。
研究设计与样本
- 回顾性队列研究,纳入2007年确诊AK并随后配取5-氟尿嘧啶或咪喹莫特的成年健康计划成员,共5700例。
- 随访识别后续AK,估计2年短期与5年长期累积风险差异,并控制治疗前变量混杂。
主要发现
- 5-氟尿嘧啶降低短期后续AK累积风险差异为-4.54%(95%CI -7.91%至-1.17%)。
- 长期累积风险差异为-1.43%(95%CI -3.43%至0.05%),无统计学显著证据。
临床怎么用
- 短期预防后续AK可优先考虑5-氟尿嘧啶,但长期获益与咪喹莫特无显著差异。
局限性
- 回顾性研究,对所有相关潜在混杂变量的 ascertainment 有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The most widely used topical agents for the field-based treatment of multiple actinic keratoses (AKs) are 5-fluorouracil and imiquimod, but their comparative effectiveness has not been assessed in a real-world setting. OBJECTIVE: We compared the effectiveness of 5-fluorouracil and imiquimod in reducing risk for subsequent AKs in a large, integrated health care delivery system in northern California. METHODS: In this cohort study, we identified adult health plan members who had an AK diagnosed in 2007 and who subsequently filled a prescription for 5-fluorouracil or imiquimod (N = 5700). We followed subjects for subsequent AKs identified by the International Classification of Diseases codes and estimated the 2-year (short-term) and 5-year (long-term) differences in cumulative risk while controlling for potential confounding by pretreatment variables. RESULTS: 5-Fluorouracil reduced the short-term incidence of subsequent AKs (cumulative risk difference -4.54% [95% confidence interval, -7.91% to -1.17%]), but there was no statistically significant evidence of a long-term decreased risk (cumulative risk difference -1.43% [95% confidence interval, -3.43% to 0.05%]) compared with that with imiquimod. LIMITATIONS: This is a retrospective study with limited ascertainment of all relevant potential confounding variables. CONCLUSION: We found that 5-fluorouracil appeared to be significantly more effective than imiquimod in the short-term, but not long-term, prevention of subsequent AKs.
引用
- Neugebauer R, Levandoski KA, Zhu Z, et al. A real-world, community-based cohort study comparing the effectiveness of topical fluorouracil versus topical imiquimod for the treatment of actinic keratosis. J Am Acad Dermatol. 2017. PMID: 29277731. doi:10.1016/j.jaad.2017.12.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。